Richiedi una copia del documento: Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression : lesson Learned for Future Trials With EGFR/MET Dual Inhibition

Captcha code
Annulla